Equatorial Guinea vs Thailand: Average cost of drugs for extensively drug-resistant tuberculosis
Equatorial Guinea
1,500 constant 2022 US$
in 2024
Thailand
1,561 constant 2022 US$
in 2024
Equatorial Guinea rank
33rd
Thailand rank
32nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Equatorial Guinea
- Thailand
How they compare
Thailand currently reports 1,561 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea, a difference of 61 constant 2022 US$.
The two have swapped places 5 times across 6 shared years of data; in 2019 it was Equatorial Guinea ahead.
Equatorial Guinea ranks 33rd and Thailand ranks 32nd of 56 countries.
Across the 2 decades both report, Equatorial Guinea averaged higher in 1 and Thailand in 1.
Head to head by decade
| Decade | Equatorial Guinea | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,000 constant 2022 US$ | 2,745 constant 2022 US$ | 1,255 constant 2022 US$ | Equatorial Guinea |
| 2020s | 2,301 constant 2022 US$ | 2,431 constant 2022 US$ | 129.8 constant 2022 US$ | Thailand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Equatorial Guinea or Thailand?
- Thailand, at 1,561 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Equatorial Guinea and Thailand?
- 61 constant 2022 US$, with Thailand ahead.
- How many years of comparable data are there for Equatorial Guinea and Thailand?
- 6 years are reported by both, from 2019 to 2024.
- How do Equatorial Guinea and Thailand rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Equatorial Guinea ranks 33rd and Thailand ranks 32nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.